NCT02273752 - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Estrogen Receptor-positive Breast CancerGastrinomaGlucagonomaHER2-negative Breast CancerInsulinomaMucositisOral ComplicationsPancreatic Polypeptide TumorProgesterone Receptor-positive Breast CancerRecurrent Breast CancerRecurrent Islet Cell CarcinomaRecurrent Renal Cell CancerSomatostatinomaStage III Renal Cell CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerStage IV Renal Cell Cancer

Interventions

DRUG

Everolimus

Given PO

Trial Locations (2)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University/Winship Cancer Institute, Atlanta